A new testosterone therapy treatment is on the market and FDA-approved. Endo Pharmaceuticals Inc. made the announcement on March 6th, 2014 about its product, AVEED, an injection for men with hypogonadism, or low testosterone. It was approved on March 5th, 2014. AVEED (testosterone undecanoate) is…
In 2006, a study by researchers at Duke University reported that Risperdal could cause gynecomastia—breast growth in males. Adolescents who took Risperdal exhibited significantly higher levels of “prolactin,” a hormone that stimulates breast development in women. After that, several more studies fou
Those at the Endocrine Society believe “large scale, prospective, randomized controlled trials” are needed to decide what the risks and benefits are associated with testosterone therapy treatment. Specifically, the Endocrine Society wants trials involving older men who are experiencing a natural de
An antipsychotic drug, Risperdal, was first marketed and FDA-approved to treat schizophrenia in adults in 1993. In 2003, it was approved to treat bipolar disorder, autism in children and teens in 2006 and in 2007 for children with schizophrenia, followed by an approval of the…
It is one of the largest health care fraud settlements in United States history. Janssen Pharmaceuticals Inc., and Johnson & Johnson, the parent company of the antipsychotic drug, Risperdal, will pay more than $2.2 billion in criminal and civil investigations. It was alleged that from…
The FDA is investigating the risk of heart attack, stroke and death among men taking different forms of testosterone therapy. This announcement came after two recent studies, one published in PLOS One, and the other in the Journal of the American Medical Association (JAMA). History…
Risperdal (risperidone) was the first antipsychotic drug marketed in the U.S. after clozapine. It was approved to treat schizophrenia in adults in 1993. The drug has since been linked to an increased risk for diabetes. A 2003 study published in the National Center for Biotechnology…
Risperdal, manufactured by Johnson & Johnson and its Janssen Pharmaceuticals subsidiary was approved for use by the FDA in 1993 to treat schizophrenia. Since then it was approved for use in 2003 for bipolar disorder, in 2006 for irritability in children and teenagers with autism,…
News of the FDA investigating the risk of heart attack, stroke and death in men taking testosterone therapy treatments appears to already be having an impact on the sale of the company’s stock, and not just in the United States. In an article published in…
On February 4, 2014, five lawsuits were filed in Illinois federal court against AbbVie Inc., and Abbott Laboratories, Inc., the manufacturers of Androgel, a testosterone therapy treatment. This Androgel lawsuit comes just days after the U.S. Food and Drug Administration (FDA) announced that it is…
Boehringer Ingelheim, the manufacturer of blood-thinning drug Pradaxa, was recently fined nearly $1 million because it allegedly lost and destroyed important files. District Judge David Herndon, who is overseeing the coordinated Pradaxa lawsuits currently proceeding in the Southern District of Illin
Is testosterone therapy more of a benefit or risk for male patients? It’s a question once again under the microscope after a 2014 PLOS One study looked at the risk of acute non-fatal myocardial infarction (MI) after men were prescribed a form of testosterone therapy. …